NR3C1 and cancer: For external validation, we combined 5‐FU sensitivity data from the Genomics of Drug Sensitivity in Cancer (GDSC) database[26] with previous H3K27Ac ChIP‐Seq data of GC cells from Patrick Tan's study (GSE186521).[27] Consistently, all 5‐FU resistant cells (top three cell lines: HS‐746T, MKN7, and RERFGC18) had SEs or enhancers around the SE regions of NR3C1, while only a few enhancers were present around the SE regions of NR3C1 in 5‐FU sensitive cells (bottom four cell lines: AGS, IM95, HGC27, and SNU16) (Figure 2J).